VistaGen
Therapeutics employs the expertise of company co-founder and renowned Canadian
stem cell scientist Dr. Gordon Keller, as well as co-founder, president, and
chief scientific officer Dr. Ralph Snodgrass.
Human
Clinical Trials in a Test Tube™, the company’s human pluripotent stem cell
(hPSC) technology platform, was developed using a combination of proprietary
and exclusively licensed hPSC technologies, including those originating from
two decades of research by Drs. Keller and Snodgrass.
The
platform’s underlying technologies enable controlled differentiation of hPSCs
into mature human cells specific to VistaGen’s current and potential predictive
toxicology, drug metabolism, drug rescue, and regenerative cell therapy
programs and commercial programs.
Utilizing
these technologies, VistaGen is currently developing CardioSafe 3D™, a novel
biological assay system that uses mature human heart cells derived from hPSCs
to screen for heart toxicity in connection with the company’s drug rescue
activities; LiverSafe 3D™, for predicting liver toxicity and metabolism issues
in connection with the company’s drug rescue activities; and AV-101, a novel,
orally available prodrug candidate focused on the treatment of neuropathic
pain, depression, and potentially other neurological conditions.
VistaGen’s
overarching goal is to combine its hPSC technology with medicinal chemistry to
generate new, proprietary, chemical variants of small molecule drug candidates
that were shelved due to unexpected heart or liver safety concerns.
The
company believes its Human Clinical Trials in a Test Tube™ platform enables a
more rapid and precise safety profile of drug rescue variants, allowing the
company to generate a pipeline of drug rescue variants that it will license or
sell to biotechnology and pharmaceutical companies that can further develop the
products and bring them to market.
For
more information, visit www.vistagen.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
